Hereditary C1q deficiency and systemic lupus erythematosus. 1994

P Bowness, and K A Davies, and P J Norsworthy, and P Athanassiou, and J Taylor-Wiedeman, and L K Borysiewicz, and P A Meyer, and M J Walport
Department of Medicine, Hammersmith Hospital, London, UK.

We describe a 27-year-old women with systemic lupus erythematosus, C1q deficiency and cytomegalovirus retinitis. She suffered from severe SLE, with cutaneous and CNS involvement, and died of CNS disease aged 28. Review of 29 other published cases of C1q deficiency shows that SLE in these patients is often severe (five with CNS disease, ten with glomerulonephritis). The results of autoantibody studies in this and another patient with C1q deficiency and SLE are presented--both patients had autoantibodies to the extractable nuclear antigens, Sm, RNP and Ro, and one patient had high titres of antibodies to dsDNA. One of the patients had previously been treated with fresh frozen plasma, and antibodies to C1q were present in his serum. Homozygous C1q deficiency is associated with a very high prevalence of severe SLE with the full panoply of autoantibodies characteristic of this disease.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003171 Complement Pathway, Classical Complement activation initiated by the binding of COMPLEMENT C1 to ANTIGEN-ANTIBODY COMPLEXES at the COMPLEMENT C1Q subunit. This leads to the sequential activation of COMPLEMENT C1R and COMPLEMENT C1S subunits. Activated C1s cleaves COMPLEMENT C4 and COMPLEMENT C2 forming the membrane-bound classical C3 CONVERTASE (C4B2A) and the subsequent C5 CONVERTASE (C4B2A3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Classical Complement Pathway,Classical Complement Activation Pathway,Complement Activation Pathway, Classical
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D014792 Visual Acuity Clarity or sharpness of OCULAR VISION or the ability of the eye to see fine details. Visual acuity depends on the functions of RETINA, neuronal transmission, and the interpretative ability of the brain. Normal visual acuity is expressed as 20/20 indicating that one can see at 20 feet what should normally be seen at that distance. Visual acuity can also be influenced by brightness, color, and contrast. Acuities, Visual,Acuity, Visual,Visual Acuities

Related Publications

P Bowness, and K A Davies, and P J Norsworthy, and P Athanassiou, and J Taylor-Wiedeman, and L K Borysiewicz, and P A Meyer, and M J Walport
October 1999, Ugeskrift for laeger,
P Bowness, and K A Davies, and P J Norsworthy, and P Athanassiou, and J Taylor-Wiedeman, and L K Borysiewicz, and P A Meyer, and M J Walport
March 2000, The British journal of dermatology,
P Bowness, and K A Davies, and P J Norsworthy, and P Athanassiou, and J Taylor-Wiedeman, and L K Borysiewicz, and P A Meyer, and M J Walport
January 2016, Frontiers in immunology,
P Bowness, and K A Davies, and P J Norsworthy, and P Athanassiou, and J Taylor-Wiedeman, and L K Borysiewicz, and P A Meyer, and M J Walport
June 2007, Annals of the New York Academy of Sciences,
P Bowness, and K A Davies, and P J Norsworthy, and P Athanassiou, and J Taylor-Wiedeman, and L K Borysiewicz, and P A Meyer, and M J Walport
April 1996, Arthritis and rheumatism,
P Bowness, and K A Davies, and P J Norsworthy, and P Athanassiou, and J Taylor-Wiedeman, and L K Borysiewicz, and P A Meyer, and M J Walport
August 1998, Immunobiology,
P Bowness, and K A Davies, and P J Norsworthy, and P Athanassiou, and J Taylor-Wiedeman, and L K Borysiewicz, and P A Meyer, and M J Walport
August 1987, The British journal of dermatology,
P Bowness, and K A Davies, and P J Norsworthy, and P Athanassiou, and J Taylor-Wiedeman, and L K Borysiewicz, and P A Meyer, and M J Walport
November 1993, Clinical and experimental immunology,
P Bowness, and K A Davies, and P J Norsworthy, and P Athanassiou, and J Taylor-Wiedeman, and L K Borysiewicz, and P A Meyer, and M J Walport
January 1984, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
P Bowness, and K A Davies, and P J Norsworthy, and P Athanassiou, and J Taylor-Wiedeman, and L K Borysiewicz, and P A Meyer, and M J Walport
March 1979, Annales de dermatologie et de venereologie,
Copied contents to your clipboard!